Gibson Dunn Advises Serapha Bio on Merger with Boundless Bio and $230 Million Financing

Gibson Dunn is advising Serapha Bio on its merger with Boundless Bio and a $230 million private financing, with a team addressing various legal aspects including tax, benefits, antitrust, and regulatory matters.